ReviewDrugs2019
Management of Post-transplant Hyperparathyroidism and Bone Disease.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Impact of vitamin D supplementation on the outcomes of kidney transplant recipients: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Timing of parathyroidectomy in kidney transplant candidates: a systematic review and a proposed clinical algorithm.Frontiers in endocrinology · 2026Pooled it
- Percutaneous nephrolithotomy for adult renal transplant de novo graft lithiasis: a single center analysis and systematic review of the literature.World journal of urology · 2024Pooled it
- Cautious clinical interpretation of preoperative Tc-Surgery in practice and science · 2026Article
- Bone Mineral Density Loss After Kidney Transplantation: Metabolic Determinants, Diagnostic Approaches, and Preventive Strategies.Kidney international reports · 2026Review
- Calcium Crystal Deposits in Kidney Allografts: The Interplay of PTH Levels and Phosphaturia.Kidney medicine · 2026Article
- Parathyroidectomy timing for persistent hyperparathyroidism in kidney transplant candidates and recipients: from secondary to tertiary disease: a literature review.Gland surgery · 2026Review
- Incidence, risk factors and survival outcomes of post-transplant tertiary hyperparathyroidism in kidney recipients.World journal of transplantation · 2026Article
- Awareness of post-transplant endocrine disorders among kidney transplant clinicians: results of an Italian survey.Journal of endocrinological investigation · 2026Article
- Predictors of Hungry Bone Syndrome After Parathyroidectomy in Secondary Hyperparathyroidism: A Narrative Review of Bone Turnover Biomarkers and Risk Prediction Tools.Journal of clinical medicine · 2025Review
- Article
- A novel nomogram for predicting the risk of persistent hyperparathyroidism after kidney transplantation.Endocrine · 2024Article
- Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persistent Hyperparathyroidism: A Retrospective Study.Annals of transplantation · 2024Article
- [Pattern of biochemical markers of mineral and bone disorders in kidney transplant recipients: real-world data].Problemy endokrinologii · 2023Article
- Hyperparathyroidism at 1 year after kidney transplantation is associated with graft loss.Surgery · 2023Article
- Is Hyperparathyroidism a Concern for Allograft Dysfunction in Pediatric Kidney Transplantation?Kidney international reports · 2023Article
- Systematic Review of the Treatment of Persistent Hyperparathyroidism Following Kidney Transplantation.Biomedicines · 2022Review
- A roadmap to parathyroidectomy for kidney transplant candidates.Clinical kidney journal · 2022Review
- The Influence of Parathyroidectomy on Osteoporotic Fractures in Kidney Transplant Recipients: Results from a Retrospective Single-Center Trial.Journal of clinical medicine · 2022Article
- Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?Journal of nephrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.